Biocept Inc. (BIOC)
Biocept Statistics
Share Statistics
Biocept has 1.04M shares outstanding. The number of shares has increased by -84.48% in one year.
| Shares Outstanding | 1.04M |
| Shares Change (YoY) | -84.48% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 2.62M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.28 and the forward PE ratio is null. Biocept's PEG ratio is 0.
| PE Ratio | -0.28 |
| Forward PE | n/a |
| PS Ratio | 0.35 |
| Forward PS | null |
| PB Ratio | 1.01 |
| P/FCF Ratio | -0.64 |
| PEG Ratio | 0 |
Enterprise Valuation
Biocept has an Enterprise Value (EV) of 8.2M.
| EV / Sales | 0.32 |
| EV / EBITDA | -0.27 |
| EV / EBIT | -0.62 |
| EV / FCF | -0.58 |
Financial Position
The company has a current ratio of 2.97, with a Debt / Equity ratio of 1.37.
| Current Ratio | 2.97 |
| Quick Ratio | 2.83 |
| Debt / Equity | 1.37 |
| Debt / EBITDA | -0.4 |
| Debt / FCF | -0.86 |
| Interest Coverage | -101.21 |
Financial Efficiency
Return on Equity is -362.16% and Return on Invested Capital is -117.56%.
| Return on Equity | -362.16% |
| Return on Assets | -103.93% |
| Return on Invested Capital | -117.56% |
| Revenue Per Employee | $517.16K |
| Profits Per Employee | $-641.74K |
| Employee Count | 50 |
| Asset Turnover | 0.84 |
| Inventory Turnover | 37.57 |
Taxes
| Income Tax | -125K |
| Effective Tax Rate | 0.39% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.59, so Biocept's price volatility has been higher than the market average.
| Beta | 0.59 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.36 |
| 200-Day Moving Average | 1.54 |
| Relative Strength Index (RSI) | 61.35 |
| Average Volume (20 Days) | - |
Income Statement
In the last 12 months, Biocept had revenue of 25.86M and earned -32.09M in profits. Earnings per share was -56.78.
| Revenue | 25.86M |
| Gross Profit | -2.58M |
| Operating Income | -31.98M |
| Net Income | -32.09M |
| EBITDA | -30.33M |
| EBIT | -31.9M |
| Earnings Per Share (EPS) | -56.78 |
Balance Sheet
The company has 12.9M in cash and 12.11M in debt, giving a net cash position of 788K.
| Cash & Cash Equivalents | 12.9M |
| Total Debt | 12.11M |
| Net Cash | 788K |
| Retained Earnings | -298.44M |
| Total Assets | 22.1M |
| Working Capital | 3.96M |
Cash Flow
In the last 12 months, operating cash flow was -13.29M and capital expenditures -807K, giving a free cash flow of -14.1M.
| Operating Cash Flow | -13.29M |
| Capital Expenditures | -807K |
| Free Cash Flow | -14.1M |
| FCF Per Share | -24.94 |
Margins
Gross margin is -9.99%, with operating and profit margins of -123.69% and -124.09%.
| Gross Margin | -9.99% |
| Operating Margin | -123.69% |
| Pretax Margin | -124.57% |
| Profit Margin | -124.09% |
| EBITDA Margin | -117.29% |
| EBIT Margin | -123.69% |
| FCF Margin | -54.51% |
Dividends & Yields
BIOC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -357.1% |
| FCF Yield | -156.87% |
Analyst Forecast
Currently there are no analyst rating for BIOC.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on May 17, 2023. It was a backward split with a ratio of 1:30.
| Last Split Date | May 17, 2023 |
| Split Type | backward |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | -25.06 |
| Piotroski F-Score | 2 |